Astellas Pharma, Inc.

Streptococcus pneumoniae Vaccine

Affinivax and Astellas entered into an exclusive worldwide license agreement in February, 2017, to develop and commercialize a vaccine targeting Streptococcus pneumoniae. The strategic partnership leverages Affinivax’s proprietary MAPS vaccine technology platform and utilizes Affinivax’s product development, analytical and manufacturing expertise to advance a novel pneumococcal MAPS vaccine. Astellas assumes a leadership role in development and commercialization, with support from Affinivax. This has resulted in the development of ASP3772, a novel vaccine which includes 24 serotypes and offers the potential to provide broader protection against pneumococcal disease than currently available vaccines. Astellas fully funds the development program and will obtain worldwide rights to commercialize the MAPS vaccine. Affinivax is eligible to receive a range of development and commercial milestones, and tiered royalties on any future product sales. ASP3772 has completed a Phase 2 clinical trial in adults.

Klebsiella pneumoniae and Pseudomonas aeruginosa Vaccine

Affinivax entered into a research collaboration and development agreement In September 2015 with Nosocomial Vaccine Corporation, or NVC, under which Affinivax and NVC agreed to work together, and with the University of Maryland to develop MAPS vaccine products targeting Klebsiella pneumoniae and Pseudomonas aeruginosa. All activities under the research collaboration and development agreement are fully funded by Astellas under a separate agreement between NVC and Astellas. In October 2019, Astellas acquired NVC and NVC became a wholly-owned subsidiary of Astellas.

The Bill & Melinda Gates Foundation

Affinivax was founded with an initial seed investment from The Bill & Melinda Gates Foundation in 2014. This investment fits with the focus of the Foundation to identify and support the latest vaccine approaches that can impact global health by improving coverage, efficacy, safety and access to life-saving treatments. Affinivax shares this common vision with the Foundation and will continue to seek opportunities where MAPS vaccines could be developed to impact infectious diseases impacting children and adults in the developing world.

Back to Top

This links to an external website.